Navigation Links
InterMune to Divest Actimmune® (Interferon Gamma-1b)
Date:5/21/2012

scribing information regarding Actimmune, including the product's safety profile, by visiting www.actimmune.com.

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to our expectations of the uses of the capital from the divesture of Actimmune for investing in the registration and commercialization of Esbriet and the cash infusion to execute our Vision 2015 strategic plan.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from any results expressed or implied by such forward-looking statements. For example, there are risks associated with the closing of the transaction for the divesture of Actimmune, including the ability o
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 6, 2015   GenSpera, Inc. (OTCQB: GNSZ) announced ... the national phase application process in 17 countries and regions, ... , China , Brazil ... When awarded, the resulting patent application will extend the exclusivity ... technology, including its lead drug candidate, mipsagargin, until 2033. ...
(Date:5/6/2015)... -- Adaptive Biotechnologies, a leader and pioneer in ... receptors in the immune system, announced today the ... a $195 million investment to support several strategic ... Capital Management and included other new investors Senator ... an additional large healthcare investor, alongside participation from ...
(Date:5/6/2015)... Medizone International, Inc. (The ... Disinfection System, have recently announced that the same ... in autoclaves, may also be used to confirm ... disinfection. Biological indicators are considered the ... lethality of a given cleaning process and are ...
Breaking Medicine Technology:GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations 2Adaptive Biotechnologies Enhances Leading Position in Growing Immunosequencing Market with Completion of $195 Million Investment 2Hospital Rooms Cleaned to Autoclave Standards 2
... Biopharmaceuticals,Corporation (TSX: NVN) announced today that the Company,s ... is scheduled to present a,Company overview at the ... Convention being held in San Diego,California, July 17-20, ... 18, 2008, at 3:45 p.m. PDT in Room ...
... a,global provider of products and services that improve ... that it will now manufacture,compound and distribute Positron ... company,s new services for the clinical trial market ... (SNM) 55th Annual Meeting,taking place in New Orleans, ...
Cached Medicine Technology:Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials 2
(Date:5/6/2015)... (PRWEB) May 06, 2015 Imprivata ... announced that CTO David Ting will lead a discussion ... associated data security and user authentication challenges, during ... The session will focus on the benefits of creating ... which care providers and patients can share information. It ...
(Date:5/6/2015)... A quality built chicken coop condo with a wheel ... to raise chickens on a pasture. By installing a wheel ... have a chicken tractor that stands up to being moved around ... it is able to flex to uneven ground without losing its ... are fertilized, and it will help provide the chickens with fresh ...
(Date:5/6/2015)... FL- May 05, 2014 (PRWEB) May 06, 2015 ... Grant Lock accepted, on behalf of MEBC, an ... organizations from JDA Software during FOCUS 2015, JDA’s ... attendees across the manufacturing, retail and wholesale distribution ... ensuring that their clients are receiving services that ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Prime ... supplier, is excited to announce a new series ... reduce the industry’s carbon footprint while improving treatment ... feature Eco-Flex™, the world’s first waste ... a game-changer for hydrotherapists,” claims the company’s president, ...
(Date:5/6/2015)... of Prussia, PA (PRWEB) May 06, 2015 ... Process Outsourcing solutions to the Medicare Advantage, Medicare Part ... finalists in the Continuity and Resilience Team category at ... the Business Continuity Institute to recognize the outstanding contribution ... operating in the North America Region, including the USA ...
Breaking Medicine News(10 mins):Health News:Imprivata to Lead Discussion about Patient and Provider Authentication Challenges and the Internet of Things in Healthcare during Citrix Synergy 2Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... C5 Medical Werks, a subsidiary of the largest ... that Dr. Steven Hughes has joined the company as ... the business development and technical support functions for C5 ... to supporting new product development on a global level ...
... Shows Moms Seek Quality Online Tools , To Manage ... Comprehensive Web Portal CHICAGO, Jan. 7 Everyone ... in American households today. So it,s no wonder that, ... health care, "Mother knows best." But until now, busy ...
... deadly lung disease , , WEDNESDAY, Jan. 7 (HealthDay News) -- Stemming ... on the older and bigger mice. They,re the ones most likely ... found. , Known as the Sin Nombre virus, the ... and feces -- causes a lung disease in people that has ...
... 2009Dedicated to the memory and scientific accomplishments of Dr. ... vasculogenesis and shed light on the link between blood ... issue (Volume 6, Number 3-4) of Lymphatic Research ... reflect the research impact of one of the pre-eminent ...
... Total Occlusion (CTO) Summit is a two-day ... new developments in therapeutic procedures that are ... success in chronic total coronary occlusions. The ... the field, case review sessions, and numerous ...
... Ill. Parents of a child born with cleft lip ... sure their child lives a normal life. For some, ... tradition of volunteering and philanthropy, members of the American Society ... "it is better to give than to receive," by traveling ...
Cached Medicine News:Health News:Dr. Steven Hughes Joins Medical Ceramics Provider: C5 Medical Werks 2Health News:KnowYourTeeth.com Launches as the Internet's New Go-To Resource for 'All Things Dental' 2Health News:KnowYourTeeth.com Launches as the Internet's New Go-To Resource for 'All Things Dental' 3Health News:KnowYourTeeth.com Launches as the Internet's New Go-To Resource for 'All Things Dental' 4Health News:KnowYourTeeth.com Launches as the Internet's New Go-To Resource for 'All Things Dental' 5Health News:Old, Fat Mice Blamed for Virus Transmission 2Health News:Festschrift Issue honoring Judah Folkman, M.D., in Lymphatic Research and Biology 2Health News:New year brings new hope to children born with cleft lip, palate 2
... is engineered to set a new standard ... is enter the patient demographics, select auto ... Windows based system uses the latest in ... versatility of the IQmark Holter algorithm. Simple, ...
... and Alpha-Beta and TCA to deliver immediate-even-visible ... used for many years to treat facial ... pregnancy and other superficial skin problems. , ... of the upper layers of skin. Normally ...
... PCA Peel® formula, this peel will ... exfoliation for oilier, thicker and more ... on extremely sun damaged and thickened ... those with active/cystic acne and asphyxiated ...
It works by stimulating new growth of skin and collagen by decreasing the bond that holds dead skin cells on the surface. This allows dead cells to be removed gradually, leaving behind a layer of smo...
Medicine Products: